STTK ▼ -0.3% - Shattuck Labs, Inc.
$STTK - Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
01-OCT-2026 07:00 AM ET
Share this post
More filings for $STTK
STTK ▲ +0.7% - Shattuck Labs, Inc.Sep 2, 2026$STTK SEC Filing Update (17-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 18, 2026$STTK SEC Filing Update (17-JUN-2026) | ThinkSabio - Stocks SimplifiedJun 17, 2026$STTK SEC Filing Update (15-JUN-2026) | ThinkSabio - Stocks SimplifiedJun 15, 2026$STTK SEC Filing Update (11-JUN-2026) | ThinkSabio - Stocks SimplifiedJun 12, 2026
View full $STTK filing history →💬 Comments
Loading comments…
Leave a comment